Navigation Links
Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
Date:11/19/2008

nd equipment, net and Other assets 7,400,495 9,194,668 Total Assets $112,469,446 $136,231,087 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities $15,718,060 $17,287,952 Long-Term Liabilities: Convertible Notes 84,650,000 125,000,000 Deferred license revenue and other 8,413,214 9,166,440 Total Long Term Liabilities 93,063,214 134,166,440 Total Liabilities 108,781,274 151,454,392 Stockholders' equity (deficit) 3,688,172 (15,223,305) Total Liabilities and Stockholders' Equity (Deficit) $112,469,446 $136,231,087 CYBERONICS, INC. AND SUBSIDIARY CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) For the Thirteen Weeks For the Twenty-Six Weeks Ended Ended October 24, October 26, October 24, October 26, 2008 2007 2008 2007 Net sales $36,031,971 $28,946,696 $69,763,829 $58,022,165 Cost of sales 5,177,800 4,576,104 9,994,562 10,127,871 Gross Profit 30,854,171 24,370,592 59,769,267 47,894,294 Operating Expenses: Selling, general and administrative 21,531,424 22,092,842 43,056,191 47,217,935 Research and development 4,806,220 5,886,095 9,414,395 12,193,818 Total Operating Expenses 26,337,644 27,978,937 52,470,586 59,411,753 Income (loss) from Operations 4,516,527 (3,608,345) 7,298,681
'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
2. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
3. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike
4. Cyberonics to Present at UBS Global Life Sciences Conference
5. Cyberonics to Present at Canaccord Adams 28th Annual Global Growth Conference
6. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results
7. Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference
8. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
11. Cyberonics Licenses Obesity-Related Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
Breaking Medicine News(10 mins):Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2
...tudy of its kind, a Mexican health care program cr... crippling health care costs among poorer househol...Popular program, and arise from an evaluation cond... establish that the program achieved its main goal...
...th in Long-Term Survivors of Hereditary Retinoblas...stoma are at an increased risk of death due to a s... Retinoblastoma is a very rare cancer of the eye ...he risk of death due to these subsequent cancers i...
...te have found that the growth factor known as TGF-... in the retina and that blocking it can cause reti...April 2 issue of PLoS ONE , may have an important...hey add to our understanding of the molecules that...
...ement of these growths needs to be tailored , ...e cancer cell can lead to multiple, anatomically d...e types of tumors usually look similar, but, until...dy by a team at the Indiana University School of M...
...e interventions in future, study finds , ,...ve treatment in the first two years after a diagno...ove patient survival, a new study finds. , Researc...ceived the most intensive treatment was $7,131 com...
...nd should be urged, expert says, , , TUESD...of moderate exercise will not harm people with hea... a new study has found. , That admittedly tepid co...e. , Some were started on a 36-session training pr...
Other Medicine News:Health News:Mexican health care program successful at reducing crippling health care costs 2Health News:Mexican health care program successful at reducing crippling health care costs 3Health News:Also in the April 7 JNCI 2Health News:Also in the April 7 JNCI 3Health News:Also in the April 7 JNCI 4Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:Single Cell May Produce Multiple Lung Cancer Tumors 2Health News:Intensive Early Treatment Doesn't Help Bladder Cancer Survival 2Health News:Exercise Might Benefit Some With Heart Failure 2Health News:Exercise Might Benefit Some With Heart Failure 3
(Date:12/4/2009)OMAHA, Neb., Dec. 4 Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services. For nearly 15 years,
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 1Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 2Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred 4865 3The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 1The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 2The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 3The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 4The Blue Foundation for a Healthy Florida Receives Grant to Address National Regional Nursing Shortages 54735 5Laureate Pharma Elects New Board Member 13606 1Laureate Pharma Elects New Board Member 13606 2
...nced Cancer Patients, ROCKVILLE, Md., April 9, 20...age pharmaceutical company developing,therapeutics...ases, today,announced that it has commenced a Phas...e inhibitor, ENMD-2076, in advanced cancer patient...ancer Center, will serve as,co-principal investiga...
...tivity of CR011-vcMMAE for ...results to be presented in June at 2008 ASCO ... Conn., April 9, 2008 CuraGen,Corporation (Nasdaq...any,focused on oncology, announced today that it h...te (ADC), into Phase II for the treatment of patie...
Other Medicine Technology:EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4
MONOJECT Red/Yellow Mottled Stopper
MONOJECT Black Stopper
VACUETTE Paediatric Fluoride Tubes - Ridged (safety screw cap)
BD Vacutainer® Fluoride Tubes - Plastic
Medicine Products: